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Deflazacort (DFZ) is a glucocorticoid used as an anti-inflammatory and immunosuppressant drug. No 
official methods are available for DFZ determination in pharmaceutical formulations. The objective of 
this study was to develop, validate and compare spectrophotometric (UV and colorimetric) and high-
performance liquid chromatography (HPLC) methods, for the quantitative determination of DFZ in tablets 
and oral suspension. For the UV method, ethanol was used as the solvent, with detection at 244 nm. The 
colorimetric method was based on the redox reaction with blue tetrazolium in alkaline medium, with 
detection at 524 nm. The method by HPLC was carried out using a C
18
 column, mobile phase consisting 
of acetonitrile:water (80:20, v/v) with a flow rate of 1.0 mL min-1 and detection at 244 nm. The methods 
proved linear (r > 0.999), precise (RSD < 5%) and accurate (recovery > 97%). Statistical analysis of the 
results indicated that the UV and HPLC methods were statistically equivalent, while the values obtained 
for the colorimetric method differed significantly from the other methods.
Uniterms: Deflazacort/quantitative determination. High performance liquid chromatography/quantitative 
analysis. Spectrophotometry/quantitative analysis. Medicines/quantitative analysis.
O deflazacorte (DFZ) é um fármaco glicocorticóide usado como antiinflamatório e imunossupressor. 
Métodos oficiais não estão disponíveis para a determinação de DFZ em formas farmacêuticas. Este estudo 
teve como objetivo desenvolver, validar e comparar métodos por espectrofotometria (UV e colorimetria) 
e cromatografia líquida de alta eficiência (CLAE), na determinação quantitativa de DFZ em comprimidos 
e suspensão oral. O método por UV utilizou etanol como solvente, com detecção em 244 nm. O método 
colorimétrico foi baseado na reação de redução com azul de tetrazólio em meio alcalino, com detecção 
em 524 nm. O método por CLAE utilizou coluna C
18
; fase móvel constituída de acetonitrila:água (80:20, 
v/v), com fluxo de 1,0 mL min-1 e detecção em 244 nm. Os métodos foram lineares (r > 0,999); precisos 
(RSD < 5 %), e exatos (recuperação > 97%). As análises estatísticas dos resultados obtidos indicaram 
que os métodos por UV e por CLAE foram estatisticamente equivalentes, enquanto os valores obtidos 
para o método colorimétrico diferiram significativamente dos demais métodos.
Unitermos: Deflazacorte/determinação quantitativa. Cromatografia líquida de alta eficiência/análise 
quantitativa. Espectrofotometria/análise quantitativa. Medicamentos/análise quantitativa.
INTRODUCTION
Deflazacort (DFZ) (Figure 1) is an oxazoline 
(1-(1,16)-21-(acetyloxy)-11-hydroxy-2-methyl-5H-
pregna-1,4-dieno[17,16-d]oxazole-3,20-dione) (O’Neil, 
2006) derivative of prednisolone with anti-inflammatory 
and immunosuppressive action (Markham, Bryson, 1995). 
The drug has been prescribed for treatment of rheumatoid 
arthritis, asthma and other conditions (Biggar et al., 2006; 
Angelini, 2007; Ferraris et al., 2007), and is a corticoste-
roid with a lower risk of side effects than other available 
steroids (Biggar et al., 2006; Angelini, 2007; Ferraris et 
al., 2007; Gonzalez-Castañeda et al., 2007).
DFZ is currently available as tablets and as an oral 
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suspension. Several high performance liquid chromato-
graphic (HPLC) methods have been reported for deter-
mination of DFZ and its metabolites in biological fluids 
(Bernareggi et al., 1987; Santos-Montes et al., 1994; 
Reynolds, Burmaster, Fichmeier, 1994; Hirata et al., 1994; 
Möllmann et al., 1995; Rao et al., 1996; Santos-Montes, 
Isquierdo-Hornillos, 1999; Ifa et al., 2000). However, 
there is no official method for DFZ analysis in any of the 
pharmacopoeia. One report on a reversed-phase liquid 
chromatographic method with UV detection for deter-
mination of DFZ in raw material, pharmaceuticals and 
for in-vitro drug-dissolution studies has been published 
(Ozkan et al., 2003). The drug has been previously de-
termined in tablets and compounded capsules by HPLC 
methods (Corrêa et al., 2007), but its determination in an 
oral suspension has not yet been described. Moreover, no 
spectrophotometric method is available for the DFZ as-
say in pharmaceutical formulations. The aim of this study 
was to develop and validate rapid, low-cost, and selective 
methods for routine quality control analyses of tablets and 
oral suspension formulations containing DFZ. 
EXPERIMENTAL
Chemicals and Reagents
DFZ used as the reference standard was obtained 
from Pharma Nostra (99.76 %) (São Paulo, Brazil). Tablets 
(30 mg) and oral suspension (22.75 mg mL-1) were pur-
chased from the local market. The products contained the 
following excipients: Tablets : lactose, sucrose, povidone, 
crospovidone, colloidal anhydrous silica, magnesium ste-
arate, iron oxide yellow, and iron oxide red; Suspension: 
crystalline cellulose carmellose sodium, sorbitol , acetic 
acid, benzylic alcohol, polysorbate 80, water, propylene-
glycol, simethicone, xanthan gum, ammonium glycyr-
rhizinate. Water was purified using a Millipore Milli-Q 
Gradient system (São Paulo, Brazil). Ethanol, methanol, 
and acetonitrile were chromatographic grade. All chemi-
cals were analytical grade. 
Equipment and conditions
A Varian UV-VIS CARY spectrophotometer and 
a 10 mm quartz cell was used to obtain all spectral and 
absorbance measurements. HPLC experiments were per-
formed on a Shimadzu system (Shimadzu, Kyoto, Japan) 
composed of a LC-10 AD
VP 
pump, a SPD-M 10 A
VP 
Pho-
todiode Array Detector, a SCL-10 A
VP 
system controller, 
SIL-10 AD
VP 
auto injector and a degasser module. Data 
were acquired and processed by Shimadzu CLASS-VP 
5.032 software (Shimadzu, Kyoto, Japan). A C
18 
(250 x 
4.6 mm, i.d., 4 µm particle size) column was used (Luna 
Phenomenex, Torrance, CA - USA). The mobile phase 
consisted of acetonitrile: water (80:20, v/v), applied at a 
flow rate of 1.0 mL min-1. The injection volume was 20 µL 
and the detection wavelength was 244 nm.
Preparation of standard solutions
Stock solutions (1mg mL-1) for spectrophotometric 
and HPLC analysis were prepared by dissolving appropriate 
amounts of DFZ in methanol or acetonitrile, respectively. 
The stock solutions were kept refrigerated (2 – 8 °C) for up 
to 48 h. Aliquots of stock solution were diluted with ethanol 
(final concentration of 12 µg mL-1 for UV studies) or mobile 
phase (final concentration of 30 µg mL-1 for LC analyses). 
For colorimetric analysis, DFZ stock solution was diluted 
with ethanol to obtain a concentration of 100 µg mL-1. 
Two mL of this solution (200 µg) was transferred to a 
25 mL volumetric flask, then 2 mL of 0.5 % methanolic 
blue tetrazolium solution and 2 mL of 10 % ethanolic tetra-
methylammonium hydroxide were added concomitantly. 
The solution was mixed, and allowed to stand in the dark 
for 1 hour. After dilution to volume with ethanol (final con-
centration of 8 µg mL-1), the absorbance was determined, 
against a blank prepared in a similar manner. 
Preparation of sample solution
Samples of crushed tablets or mixed oral suspension 
(30 mg or 22.75 mg of DFZ, respectively) were placed in 
25 mL volumetric flasks. Approximately fifteen mL of 
either methanol (UV) or acetonitrile (HPLC) was added. 
The flasks were shaken mechanically for 15 minutes, and 
diluted to volume with their respectively solvents to ob-
tain stock sample solutions. These solutions were filtered 
through filter paper. For the UV method, the samples were 
diluted in ethanol to final concentrations of 12 µg mL-1 
FIGURE 1 - Chemical structure of deflazacort.
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(for tablets) or 14.6 µg mL-1 (for oral suspension). For the 
HPLC method, the samples were diluted with mobile pha-
se to give a final concentration of 30 µg mL-1 (for tablets) 
or 36.4 µg mL-1 (for oral suspension). For the colorimetric 
assay, the samples were diluted with ethanol to obtain 
concentrations of 20 mg mL-1 (for tablets) or 72.8 mg mL-1 
(for oral suspension). From these solutions, aliquots of 
10.0 mL (tablets) or 2.8 mL (oral suspension) were trans-
ferred to a 25 mL volumetric flask, then 2 mL of 0.5% 
methanolic blue tetrazolium solution and 2 mL of 10% 
ethanolic tetramethylammonium hydroxide were added 
concomitantly. The solution was mixed, and allowed to 
stand in the dark for 1 hour. After dilution to volume with 
ethanol (final concentration of 8 mg mL-1 for tablets and 
8.15 mg mL-1 for oral suspension) the absorbances were 
determined against a blank prepared in a similar manner. 
Method validation
Each method was validated by the determination 
of the following operational characteristics: selectivity, 
linearity, limits of detection and quantification, precision 
and accuracy, according to the procedures described in 
ICH guidelines Q2 (R1) (ICH, 2005). 
Selectivity
Selectivity was assessed by comparing the chroma-
tograms (for HPLC method) or spectra (for spectropho-
tometric methods) obtained from the drug in a mixture 
containing the most commonly used excipients with those 
obtained from a blank sample (a solution of excipients in 
water without the drug).
Linearity
Calibration curves (three different days) were obtai-
ned using six concentrations of the DFZ standard solutions 
over the ranges given in Table 1. The results obtained 
were used to calculate the equation of the regression 
line by using the linear least–squares regression method, 
and the data were also evaluated by analysis of variance 
(ANOVA). 
Detection Limit (DL) and Quantification Limit 
(QL)
DL and QL were calculated directly from the cali-
bration plot. The DL and QL were calculated as 3.3 r/S 
and 10 r/S, respectively, where r is the standard deviation 
of the intercept and S is the slope of the calibration plot. 
Precision
The repeatability (intra-day precision) of the proce-
dures was determined by analysis of six samples of tablets 
or oral suspension, at equal concentrations, during the 
same day, under identical experimental conditions. Inter-
day precision values were obtained by assaying freshly 
prepared samples of tablets or oral suspension solutions 
on 3 different days. DFZ contents and the relative standard 
deviation (R.S.D.) were calculated. 
Accuracy
Accuracy was evaluated using the percent recovery 
obtained from analysis of samples of tablets or oral sus-
pension spiked with known amounts of DFZ reference 
standard at 3 different levels. The percent recovery was 
calculated by the following equation (AOAC, 1990):
where R (%) is the percent recovery of added DFZ referen-
ce standard; Cs is DFZ concentration in the spiked sample; 
Cp is DFZ concentration in the unspiked sample; and Ca 
is the amount of DFZ reference standard added.
RESULTS AND DISCUSSION
The choice of an analytical method depends on fac-
tors such as the nature of the drug, the complexity of the 
sample, and the intended use of the method. For quality 
control in drug analysis, the simplest and fastest method is 
the most desirable. According to Görög, the predominant 
method for the assay of steroid drugs is reversed phase 
high performance liquid chromatography (RP-HPLC) 
with UV detection (Görög, 2004). However, spectropho-
tometric methods are also widely used because they are 
inexpensive and easy to perform. The spectral investiga-
tion of DFZ in different solvents (methanol, ethanol, and 
acetonitrile) and the influence of excipients present in the 
pharmaceutical formulations were also evaluated. Due 
to better solubility of the drug in ethanol and ethanol’s 
lower toxicity, this diluent was chosen for the present 
analysis. DFZ in ethanol showed an absorption maximum 
at 244 nm (Figure 2A). The colorimetric method, which 
was based on the assay for steroids described in the USP 
Pharmacopoeia, involves the redox reaction of DFZ with 
tetrazolium reagent in alkaline medium which generates 
formazen in a quantitative manner (United States Pharma-
copeia, 2007). The optimized time of the redox reaction 
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was 1 hour, and the concentration of DFZ was determined 
from the absorption at 524 nm (Figure 2B).
The HPLC method was previously validated in our 
group for DFZ assay in tablets and compounded capsu-
les (Corrêa et al., 2007). In the present paper, the HPLC 
method was extended for the determination of DFZ in 
oral suspension. Compared with the previously published 
HPLC method (Oskan et al., 2003), our method has the 
advantage of simpler mobile phase. By not using a buffe-
red system column lifetime should be increased. A typical 
chromatogram of DFZ from the oral suspension is shown 
in Figure 3.
Validation of the methods
We observed no evidence of interference from the 
excipients in the methods analyzed. For spectrophoto-
metric methods, the spectra of the samples and the DFZ 
reference spectrum showed the same maximum. For the 
HPLC method, the analytic chromatographic peak was 
not attributable to more than one component (peak purity 
test > 99%). At equal concentrations, the peak areas of the 
DFZ standard and solutions of DFZ extracted from the 
oral suspension were identical. The methods were shown 
to be selective to quantify DFZ. A linear relationship was 
found between the DFZ concentrations and the responses 
(both absorbance intensity and peak area). The linearity 
data were validated by ANOVA, which demonstrated a 
significant linear regression and no significant deviation 
from linearity (P = 0.05). The regression analyses are 
presented in Table I. High regression coefficients (r) were 
obtained for all three methods (r >0.999). 
The precision data obtained for the evaluated me-
thods are shown in Table II. The RSD (Relative Standard 
Deviation) values show that all the methods exhibited 
good repeatability (< 5.0%) for intra and inter-day preci-
sion (BRASIL, 2003).
Accuracy was investigated by means of a standard 
addition experiment. Good recovery values were obtained 
(Table III) and ranged from 95 to 105%. The validated 
spectrophotometric and HPLC methods were applied to 
the analysis of DFZ in both tablets and oral suspension.
FIGURE 2 - A – UV spectrum of deflazacort reference standard 
solution in ethanol (12 µg mL-1). B – Spectrum of the redox 
reaction of blue tetrazolium and DFZ (8 µg mL-1) by colorimetric 
analysis.
FIGURE 3 - HPLC chromatogram of DFZ obtained from oral suspension (36.4 µg mL-1), C
18 
(250 x 4.6 mm, i.d., 4 µm particle 
size) column, mobile phase consisted of acetonitrile: water (80:20, v/v), applied at a flow rate of 1.0 mL min-1, injection volume 
was 20 µL and elution of peaks was monitored at 244 nm.
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TABLE I - Overview of the linearity, detection limit (DL) and quantitation limit (QL) data obtained for deflazacort by the 
chromatographic and spectrophotometric methods
Parameters
Method
UV Colorimetric LC
Concentration range (µg mL-1) 4.0 – 24.0 2.0 – 16.0 5.0 – 50.0
Regression coefficient (r) 0.9990 0.9998 0.9998
Slope ± standard error 0.0342 ± 0.0004 0.0465 ± 0.0009 41830 ± 376.24
Intercept ± standard error 0.0063 ± 0.0068 0.0098±0.0085 1577.4 ± 11417
DL (µg mL-1) 0.12 0.23 0.18
QL (µg mL-1) 0.37 0.66 0.55
TABLE II - Precision of the evaluated methods for deflazacort determination
Oral suspension
Intra-day Inter-day
Method %± s.e.m. %RSD % ± s.e.m % RSD
UV 96.3 ± 0.6 2.1 97.9 ± 0.8 1.4
Colorimetric 99.2 ± 1.0 3.5 100.4 ± 1.5 2.6
LC 96.3 ± 0.1 0.4 95.2 ± 0.7 1.2
Tablets
Intra-day Inter-day
Method %± s.e.m % RSD %± s.e.m % RSD
UV 97.2 ± 0.5 1.1 97.2 ± 0.1 0.1
Colorimetric 101.6 ± 0.9 2.0 101.9 ± 0.8 1.3
LC 97.7 ± 0.6 1.5 98.4 ± 0.7 1.2
s.e.m. Standard error mean. RSD : Relative standard deviation.
TABLE III - Accuracy of the evaluated methods for deflazacort determination
UV Colorimetric LC
Tablets
Added (µg mL-1) 6.0 12.0 18.0 4.0 8.0 12.0 4.0 8.0 12.0
Found (µg mL-1) 6.06 12.05 18.12 3.85 7.98 12.04 3.98 7.86 11.77
Recovery (%) 101.0 100.7 100.6 97.9 99.8 100.0 99.5 98.2 98.1
Oral suspension
Added (µg mL-1) 2.0 4.0 8.0 2.0 4.0 6.0 2.5 5.0 7.5
Found (µg mL-1) 1.97 3.98 7.85 1.94 3.90 5.90 2.47 5.09 7.54
Recovery (%) 98.7 99.5 98.2 96.9 98.3 98.4 97.4 100.4 98.9
Although all three methods have shown precision 
and accuracy within the required criteria, the results 
obtained by the colorimetric method were found to be 
higher than the other methods (at least 3.5% above the 
others). The ANOVA test was also applied and revealed 
statistically significant differences among the results 
obtained by the three individual analytical methods at a 
confidence level of 0.05. Tukey’s multiple comparison 
test demonstrated that the results obtained by the HPLC 
and UV methods for both tablets and oral suspension were 
statistically equivalent (p > 0.05). However, the values 
obtained for the colorimetric method differed significantly 
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from those obtained by HPLC and UV spectrophotometric 
methods (p < 0.05), and indicated that the colorimetric 
method was not superior to the UV method based on the 
natural absorption spectrum of DFZ. The rapid assay ti-
mes of the UV spectrophotometric method and the good 
precision for this procedure are additional advantages 
of this method compared with the colorimetric method 
(Görög, 2005). The HPLC method was more selective, 
and could be applied successfully in stability studies of 
DFZ in pharmaceutical formulations.
CONCLUSION
The proposed spectrophotometric and HPLC metho-
ds were linear, accurate and specific. The results showed 
that the UV spectrophotometric and HPLC methods were 
statistically equivalent. However, the values obtained by 
the colorimetric assay differed significantly from the other 
methods, making this procedure less satisfactory than the 
UV spectrophotometric and HPLC methods. Since the UV 
spectrophotometric and HPLC methods are precise and 
simple, they may be successfully applied in quality control 
analysis of DFZ in tablets and oral suspension.
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